Ejaz Kamboj, MD
Cardiovascular Disease · Las Vegas, NVNPI 1396833810
Payments from drug & device makers
What this record shows
This record is dominated by other: $15,964 of the $24,649 with a category attached, or 64.8%. Medtronic accounts for 65.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $16,379 and has fallen 99.3% since, to $116 in 2025.
Across 70 payments — averaging $352.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Angiodynamics, Inc.$5K
- GE HealthCare$2K
- Sanofi-aventis U.S. LLC$220
- Shockwave Medical, Inc$208
- Astellas Pharma US Inc$199
- plus $1K from 17 others
Across 7 payments — averaging $405.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$3K
What the payments were for
- Speaking & faculty fees$2,0588%
- Food & beverage$1,6727%
- Education$4,95520%
- Other$15,96465%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $16,114 |
| Angiodynamics, Inc. | 2 | $4,823 |
| GE HealthCare | 1 | $2,058 |
| Sanofi-aventis U.S. LLC | 11 | $220 |
| Shockwave Medical, Inc | 1 | $208 |
| Astellas Pharma US Inc | 4 | $199 |
| Merck | 13 | $185 |
| Abbott | 2 | $162 |
| Bard Peripheral Vascular, Inc. | 6 | $102 |
| Silk Road Medical, Inc. | 1 | $101 |
| AstraZeneca | 5 | $82 |
| Novo Nordisk | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Johnson & Johnson | 4 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Boehringer Ingelheim | 1 | $29 |
| Novartis | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Medicomp Inc | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,649 in reported general payments places this provider in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $147,660 |
| EntrestoSacubitril/Valsartan | 55 | $44,346 |
| OzempicSemaglutide | 40 | $39,996 |
| XareltoRivaroxaban | 34 | $35,894 |
| JardianceEmpagliflozin | 52 | $34,899 |
| BrilintaTicagrelor | 12 | $5,329 |
| Amiodarone Hcl | 114 | $2,944 |
| Metoprolol Succinate | 237 | $2,754 |
| Prasugrel Hcl | 11 | $2,105 |
| Nifedipine ErNifedipine | 65 | $1,302 |
| Nebivolol Hcl | 16 | $1,250 |
| Atorvastatin Calcium | 113 | $1,172 |
| Quetiapine Fumarate | 40 | $927 |
| ClopidogrelClopidogrel Bisulfate | 101 | $871 |
| Losartan Potassium | 72 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $20 | $44,34655 claims |
| Novo NordiskOzempic | $81 | $39,99640 claims |
| Johnson & JohnsonXarelto | $50 | $35,89434 claims |
| Boehringer IngelheimJardiance | $29 | $34,89952 claims |
| AstraZenecaBrilinta | $82 | $5,32912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.